Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
21st Century Cures Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016.
Advancing Targeted Therapies for Rare Diseases Act of 2016
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2016 · first_quarter · Q1
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016.
Source: Senate LDA
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016.
Advancing Precision Medicine Act of 2016
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016.
Ensuring Access to Clinical Trials Act of 2015
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to the "21st Century Cures Act" Discussion Draft (no specific bills); Issues related to the "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions)
Ensuring Access to Clinical Trials Act of 2015
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions); S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015.
Ensuring Access to Clinical Trials Act of 2015
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions)
21st Century Cures Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions)
21st Century Cures Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015.
21st Century Cures Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions); S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015.
Innovation Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 9 Innovation Act (all provisions)
Innovation Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 9 Innovation Act (all provisions)
Innovation Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 9 Innovation Act (all provisions)
Innovation Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 9 Innovation Act (all provisions)
Ensuring Access to Clinical Trials Act of 2015
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to the "21st Century Cures Act" Discussion Draft (no specific bills); Issues related to the "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions)
Ensuring Access to Clinical Trials Act of 2015
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions)
Ensuring Access to Clinical Trials Act of 2015
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions); S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015.
Advancing Targeted Therapies for Rare Diseases Act of 2016
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions); S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015.
Advancing Targeted Therapies for Rare Diseases Act of 2016
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015.
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions)
Part D Beneficiary Appeals Fairness Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
Part D Beneficiary Appeals Fairness Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions).
Part D Beneficiary Appeals Fairness Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions); Issues related to the reauthorization of the Medicaid State Children's Health Insurance Program (no specific bills)
Part D Beneficiary Appeals Fairness Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
Drug Quality and Security Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
Patients' Access to Treatments Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to regulatory reforms and drug development under the Energy & Commerce Committee's 21st Century Cures initiative (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions)
Patients' Access to Treatments Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to regulatory reforms and drug development under the Energy & Commerce Committee's 21st Century Cures initiative (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions)
Patients' Access to Treatments Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
Patients' Access to Treatments Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions)
Part D Beneficiary Appeals Fairness Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
Part D Beneficiary Appeals Fairness Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
Part D Beneficiary Appeals Fairness Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions); Issues related to the reauthorization of the Medicaid State Children's Health Insurance Program (no specific bills)
Part D Beneficiary Appeals Fairness Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions).
Patent Transparency and Improvements Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
S. 1720 Patent Transparency and Improvements Act of 2013 (all provisions); H.R. 3309 Innovation Act (all provisions)
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
Part D Beneficiary Appeals Fairness Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
Part D Beneficiary Appeals Fairness Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
Drug Quality and Security Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
Drug Quality and Security Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
Patients' Access to Treatments Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
Patients' Access to Treatments Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions)
Patients' Access to Treatments Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions)
Patients' Access to Treatments Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
Part D Beneficiary Appeals Fairness Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
Part D Beneficiary Appeals Fairness Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
Patent Transparency and Improvements Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
S. 1720 Patent Transparency and Improvements Act of 2013 (all provisions); H.R. 3309 Innovation Act (all provisions)
Pandemic and All-Hazards Preparedness Reauthorization Act of 2011
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1809), all provisions; Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 (H.R. 2405, S. 1855), all provisions; (cont'd next page) Expanding and Promoting Expertise in Review of Rare Treatments Act of 2012 (H.R.4156 , S.2281), all provisions; Transforming the Regulatory Environment to Accelerate Access to Treatments (S.2113), provisions; The Unlocking Lifesaving Treatments for Rare-Diseases Act (H.R.3737), all provisions; Issues related to the 2012 Prescription Drug User Fee Act Reauthorization Discussion Draft, all provisions
Pandemic and All-Hazards Preparedness Reauthorization Act of 2011
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1809), all provisions; Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 (H.R. 2405, S. 1855), all provisions; (cont'd next page) Expanding and Promoting Expertise in Review of Rare Treatments Act of 2012 (H.R.4156 , S.2281), all provisions; Transforming the Regulatory Environment to Accelerate Access to Treatments (S.2113), provisions; The Unlocking Lifesaving Treatments for Rare-Diseases Act (H.R.3737), all provisions; The Food and Drug Administration Safety and Innovation Act (S.3187), all provisions; To amend chapter V of the Federal Food, Drug, and Cosmetic Act to expedite the development and review of breakthrough therapies (H.R.5334), all provisions; The FAST Act (H.R.4132), all provisions; The Food and Drug Administration Reform Act of 2012 (H.R.5651), all provisions.
Viral Hepatitis Testing Act of 2011
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1809), all provisions; Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 (H.R. 2405, S. 1855), all provisions; (cont'd next page) Expanding and Promoting Expertise in Review of Rare Treatments Act of 2012 (H.R.4156 , S.2281), all provisions; Transforming the Regulatory Environment to Accelerate Access to Treatments (S.2113), provisions; The Unlocking Lifesaving Treatments for Rare-Diseases Act (H.R.3737), all provisions; Issues related to the 2012 Prescription Drug User Fee Act Reauthorization Discussion Draft, all provisions
Viral Hepatitis Testing Act of 2011
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1809), all provisions.
Viral Hepatitis Testing Act of 2011
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1809), all provisions; Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 (H.R. 2405, S. 1855), all provisions; (cont'd next page) Expanding and Promoting Expertise in Review of Rare Treatments Act of 2012 (H.R.4156 , S.2281), all provisions; Transforming the Regulatory Environment to Accelerate Access to Treatments (S.2113), provisions; The Unlocking Lifesaving Treatments for Rare-Diseases Act (H.R.3737), all provisions; The Food and Drug Administration Safety and Innovation Act (S.3187), all provisions; To amend chapter V of the Federal Food, Drug, and Cosmetic Act to expedite the development and review of breakthrough therapies (H.R.5334), all provisions; The FAST Act (H.R.4132), all provisions; The Food and Drug Administration Reform Act of 2012 (H.R.5651), all provisions.
Viral Hepatitis Testing Act of 2011
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1809), all provisions.
ULTRA
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1809), all provisions; Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 (H.R. 2405, S. 1855), all provisions; (cont'd next page) Expanding and Promoting Expertise in Review of Rare Treatments Act of 2012 (H.R.4156 , S.2281), all provisions; Transforming the Regulatory Environment to Accelerate Access to Treatments (S.2113), provisions; The Unlocking Lifesaving Treatments for Rare-Diseases Act (H.R.3737), all provisions; The Food and Drug Administration Safety and Innovation Act (S.3187), all provisions; To amend chapter V of the Federal Food, Drug, and Cosmetic Act to expedite the development and review of breakthrough therapies (H.R.5334), all provisions; The FAST Act (H.R.4132), all provisions; The Food and Drug Administration Reform Act of 2012 (H.R.5651), all provisions.
ULTRA
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1809), all provisions; Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 (H.R. 2405, S. 1855), all provisions; (cont'd next page) Expanding and Promoting Expertise in Review of Rare Treatments Act of 2012 (H.R.4156 , S.2281), all provisions; Transforming the Regulatory Environment to Accelerate Access to Treatments (S.2113), provisions; The Unlocking Lifesaving Treatments for Rare-Diseases Act (H.R.3737), all provisions; Issues related to the 2012 Prescription Drug User Fee Act Reauthorization Discussion Draft, all provisions
FAST Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1809), all provisions; Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 (H.R. 2405, S. 1855), all provisions; (cont'd next page) Expanding and Promoting Expertise in Review of Rare Treatments Act of 2012 (H.R.4156 , S.2281), all provisions; Transforming the Regulatory Environment to Accelerate Access to Treatments (S.2113), provisions; The Unlocking Lifesaving Treatments for Rare-Diseases Act (H.R.3737), all provisions; The Food and Drug Administration Safety and Innovation Act (S.3187), all provisions; To amend chapter V of the Federal Food, Drug, and Cosmetic Act to expedite the development and review of breakthrough therapies (H.R.5334), all provisions; The FAST Act (H.R.4132), all provisions; The Food and Drug Administration Reform Act of 2012 (H.R.5651), all provisions.
EXPERRT Act of 2012
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1809), all provisions; Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 (H.R. 2405, S. 1855), all provisions; (cont'd next page) Expanding and Promoting Expertise in Review of Rare Treatments Act of 2012 (H.R.4156 , S.2281), all provisions; Transforming the Regulatory Environment to Accelerate Access to Treatments (S.2113), provisions; The Unlocking Lifesaving Treatments for Rare-Diseases Act (H.R.3737), all provisions; Issues related to the 2012 Prescription Drug User Fee Act Reauthorization Discussion Draft, all provisions
EXPERRT Act of 2012
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1809), all provisions; Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 (H.R. 2405, S. 1855), all provisions; (cont'd next page) Expanding and Promoting Expertise in Review of Rare Treatments Act of 2012 (H.R.4156 , S.2281), all provisions; Transforming the Regulatory Environment to Accelerate Access to Treatments (S.2113), provisions; The Unlocking Lifesaving Treatments for Rare-Diseases Act (H.R.3737), all provisions; The Food and Drug Administration Safety and Innovation Act (S.3187), all provisions; To amend chapter V of the Federal Food, Drug, and Cosmetic Act to expedite the development and review of breakthrough therapies (H.R.5334), all provisions; The FAST Act (H.R.4132), all provisions; The Food and Drug Administration Reform Act of 2012 (H.R.5651), all provisions.
To amend chapter V of the Federal Food, Drug, and Cosmetic Act to expedite the development and review of breakthrough therapies.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1809), all provisions; Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 (H.R. 2405, S. 1855), all provisions; (cont'd next page) Expanding and Promoting Expertise in Review of Rare Treatments Act of 2012 (H.R.4156 , S.2281), all provisions; Transforming the Regulatory Environment to Accelerate Access to Treatments (S.2113), provisions; The Unlocking Lifesaving Treatments for Rare-Diseases Act (H.R.3737), all provisions; The Food and Drug Administration Safety and Innovation Act (S.3187), all provisions; To amend chapter V of the Federal Food, Drug, and Cosmetic Act to expedite the development and review of breakthrough therapies (H.R.5334), all provisions; The FAST Act (H.R.4132), all provisions; The Food and Drug Administration Reform Act of 2012 (H.R.5651), all provisions.
Food and Drug Administration Reform Act of 2012
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1809), all provisions; Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 (H.R. 2405, S. 1855), all provisions; (cont'd next page) Expanding and Promoting Expertise in Review of Rare Treatments Act of 2012 (H.R.4156 , S.2281), all provisions; Transforming the Regulatory Environment to Accelerate Access to Treatments (S.2113), provisions; The Unlocking Lifesaving Treatments for Rare-Diseases Act (H.R.3737), all provisions; The Food and Drug Administration Safety and Innovation Act (S.3187), all provisions; To amend chapter V of the Federal Food, Drug, and Cosmetic Act to expedite the development and review of breakthrough therapies (H.R.5334), all provisions; The FAST Act (H.R.4132), all provisions; The Food and Drug Administration Reform Act of 2012 (H.R.5651), all provisions.
Pandemic and All-Hazards Preparedness Reauthorization Act of 2011
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1089), all provisions; Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 (H.R. 2405, S. 1855), all provisions.
Pandemic and All-Hazards Preparedness Reauthorization Act of 2011
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis and Liver Cancer Control and Prevention Act of 2010, all provisions; H.R. 2405 Pandemic and All-Hazards Preparedness Reauthorization Act of 2011, all provisions.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
FY 2012 Labor/HHS/Education (H.R. 3070 and S. 1599), provisions related to viral hepatitis funding.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
FY 2012 Labor/HHS/Education Appropriations (H.R. 3070 and S. 1599), provisions related to viral hepatitis funding
Viral Hepatitis Testing Act of 2011
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1089), all provisions; Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 (H.R. 2405, S. 1855), all provisions.
Veterans Health Care Improvement Act of 2011
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1089), all provisions; Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 (H.R. 2405, S. 1855), all provisions.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2010
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); HR 3293, H.R. 3288: FY 2010 Labor/HHS/Education Appropriations, provisions related to viral hepatitis funding; H.R.3974: Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009; all provisions; S. 3711, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2010, all provisions; FY 2011 Labor/HHS/Education Appropriations, provisions related to viral hepatitis funding.
Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); HR 3293, H.R. 3288: FY 2010 Labor/HHS/Education Appropriations, provisions related to viral hepatitis funding; H.R.3974: Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009; all provisions; S. 3711, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2010, all provisions; FY 2011 Labor/HHS/Education Appropriations, provisions related to viral hepatitis funding.
Viral Hepatitis and Liver Cancer Control and Prevention Act of 2010
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); HR 3293, H.R. 3288: FY 2010 Labor/HHS/Education Appropriations, provisions related to viral hepatitis funding; H.R.3974: Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009; all provisions; S. 3711, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2010, all provisions; FY 2011 Labor/HHS/Education Appropriations, provisions related to viral hepatitis funding.
Issues related to the Orphan Drug Tax Credit (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2015 · fourth_quarter · Q4
H.R. 9 Innovation Act (all provisions)
Issues related to the Orphan Drug Tax Credit (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015.
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2015 · third_quarter · Q3
H.R. 9 Innovation Act (all provisions)
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions); S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015.
Issues related to the Orphan Drug Tax Credit (no specific bills).
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2015 · second_quarter · Q2
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions)
Issues related to the Orphan Drug Tax Credit (no specific bills).
H.R. 9 Innovation Act (all provisions)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2015 · first_quarter · Q1
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills)
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to the "21st Century Cures Act" Discussion Draft (no specific bills); Issues related to the "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions)
Issues related to the Orphan Drug Tax Credit (no specific bills).
H.R. 9 Innovation Act (all provisions)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2014 · fourth_quarter · Q4
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions)
Issues related to the Orphan Drug Tax Credit (no specific bills)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2014 · third_quarter · Q3
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions); Issues related to the reauthorization of the Medicaid State Children's Health Insurance Program (no specific bills)
Issues related to Camp Comprehensive Tax Reform draft (no specific bills)
Issues related to regulatory reforms and drug development under the Energy & Commerce Committee's 21st Century Cures initiative (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions)
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2014 · second_quarter · Q2
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions).
Issues related to Camp Comprehensive Tax Reform draft (no specific bills); Issues related to the Orphan Drug Tax Credit (no specific bills)
Issues related to regulatory reforms and drug development under the Energy & Commerce Committee's 21st Century Cures initiative (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions)
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2014 · first_quarter · Q1
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
Issues related to the Orphan Drug Tax Credit (no specific bills)
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2013 · fourth_quarter · Q4
Issues related to the Orphan Drug Tax Credit (no specific bills)
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2013 · third_quarter · Q3
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
Issues related to the Orphan Drug Tax Credit (no specific bills)
Issues related to raising awareness of Hepatitis C (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2013 · second_quarter · Q2
Issues related to raising awareness of Hepatitis C (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2013 · first_quarter · Q1
Issues related to raising awareness of Hepatitis C (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2012 · fourth_quarter · Q4
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1809), all provisions.
FY 2013 Labor/HHS/Education Draft, provisions related to viral hepatitis funding, The Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013 (S.3295), provisions related to viral hepatitis funding.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2012 · third_quarter · Q3
FY 2013 Labor/HHS/Education Draft, provisions related to viral hepatitis funding, The Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013 (S.3295), provisions related to viral hepatitis funding.
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1809), all provisions.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2012 · second_quarter · Q2
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1809), all provisions; Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 (H.R. 2405, S. 1855), all provisions; (cont'd next page) Expanding and Promoting Expertise in Review of Rare Treatments Act of 2012 (H.R.4156 , S.2281), all provisions; Transforming the Regulatory Environment to Accelerate Access to Treatments (S.2113), provisions; The Unlocking Lifesaving Treatments for Rare-Diseases Act (H.R.3737), all provisions; The Food and Drug Administration Safety and Innovation Act (S.3187), all provisions; To amend chapter V of the Federal Food, Drug, and Cosmetic Act to expedite the development and review of breakthrough therapies (H.R.5334), all provisions; The FAST Act (H.R.4132), all provisions; The Food and Drug Administration Reform Act of 2012 (H.R.5651), all provisions.
FY 2013 Labor/HHS/Education Draft, provisions related to viral hepatitis funding, BARDA funding, and funding the Strategic National Stockpile; The Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013 (S.3295), provisions related to viral hepatitis funding, BARDA funding, and funding the Strategic National Stockpile.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2012 · first_quarter · Q1
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1809), all provisions; Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 (H.R. 2405, S. 1855), all provisions; (cont'd next page) Expanding and Promoting Expertise in Review of Rare Treatments Act of 2012 (H.R.4156 , S.2281), all provisions; Transforming the Regulatory Environment to Accelerate Access to Treatments (S.2113), provisions; The Unlocking Lifesaving Treatments for Rare-Diseases Act (H.R.3737), all provisions; Issues related to the 2012 Prescription Drug User Fee Act Reauthorization Discussion Draft, all provisions
FY 2013 Labor/HHS/Education Draft, provisions related to viral hepatitis funding, BARDA funding, and funding the Strategic National Stockpile.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2011 · fourth_quarter · Q4
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1089), all provisions; Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 (H.R. 2405, S. 1855), all provisions.
FY 2012 Labor/HHS/Education (H.R. 3070 and S. 1599), provisions related to viral hepatitis funding.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2011 · third_quarter · Q3
FY 2012 Labor/HHS/Education Appropriations (H.R. 3070 and S. 1599), provisions related to viral hepatitis funding
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis and Liver Cancer Control and Prevention Act of 2010, all provisions; H.R. 2405 Pandemic and All-Hazards Preparedness Reauthorization Act of 2011, all provisions.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2011 · second_quarter · Q2
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis and Liver Cancer Control and Prevention Act of 2010, all provisions; FY 2012 Labor/HHS/Education Appropriations, provisions related to viral hepatitis funding; S 23/HR 1249 America Invents Act, provisions related to supplemental examination, fee diversion, and first inventor to file.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2011 · first_quarter · Q1
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis and Liver Cancer Control and Prevention Act of 2010, all provisions; FY 2011 Labor/HHS/Education Appropriations, provisions related to viral hepatitis funding; S 23/HR 1249 America Invents Act, general discussions.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2010 · fourth_quarter · Q4
Issues related to raising awareness of Hepatitis C (no specific bills); HR 3293, H.R. 3288: FY 2010 Labor/HHS/Education Appropriations, provisions related to viral hepatitis funding; H.R.3974: Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009; all provisions; S. 3711, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2010, all provisions; FY 2011 Labor/HHS/Education Appropriations, provisions related to viral hepatitis funding.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S. 1720 Patent Transparency and Improvements Act of 2013 (all provisions); H.R. 3309 Innovation Act (all provisions)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S. 1720 Patent Transparency and Improvements Act of 2013 (all provisions); H.R. 3309 Innovation Act (all provisions)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE